Recce Pharmaceuticals (ASX:RCE) obtained Patent Family 3 in Australia for its R327 and R529 anti-infectives, effective until 2037, according to a Tuesday filing with the Australian bourse.
The pharmaceutical company said it is now patent-protected in all major pharmaceutical markets globally.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.